Raptiva (efalizumab)
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 53 (Table of Contents)
Published: 4 Nov-2004
DOI: 10.3833/pdr.v2004.i53.764 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
The increasing demand for a treatment that would address the key inflammatory aspects of psoriasis, rather than treating the condition with systemic immunosuppressive drugs, has brought a new generation of therapies for psoriasis, of which Raptiva™ is an example...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS